Authors: | Moskowitz, A. J.; Koch, R.; Mehta-Shah, N.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Davey, T.; Galasso, N.; Evan, M.; Shah, M.; Ganesan, N.; Lubin, L.; Kim, Y. H.; Khodadoust, M.; Almazan, T.; Dai, J.; Jacobsen, E. D.; Weinstock, D. M.; Horwitz, S. M. |
Abstract Title: | In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma |
Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
Journal Title: | Blood |
Volume: | 130 |
Issue: | Suppl. 1 |
Meeting Dates: | 2017 Dec 9-12 |
Meeting Location: | Atlanta, GA |
ISSN: | 0006-4971 |
Publisher: | American Society of Hematology |
Date Published: | 2017-12-07 |
Language: | English |
ACCESSION: | WOS:000432419402069 |
PROVIDER: | wos |
DOI: | 10.1182/blood.V130.Suppl_1.819.819 |
Notes: | Meeting Abstract: 819 -- Source: Wos |